myelodysplastic syndrome

Ivosidenib Monotherapy Shows Promise in IDH1 Mutated Myelodysplastic Neoplasm/Syndrome: A Phase 2 Study

By MedXY 08/28/2026

Ivosidenib monotherapy demonstrates substantial efficacy and safety in IDH1 mutated myelodysplastic neoplasm, especially in treatment-naïve high-risk patients, offering a new therapeutic option.

Hematology-Oncology news

Unveiling Atelis Syndrome: SLF2 and SMC5 Dysfunction as Drivers of Hematopoietic Stem Cell Aging and Myelodysplastic Syndrome Predisposition

By MedXY 08/10/2026

Dysfunction in SLF2 and SMC5 causes premature hematopoietic stem cell aging, bone marrow failure, and early-onset myelodysplastic syndrome in Atelis Syndrome, defining a novel inherited bone marrow failure disorder.

Hematology-Oncology news

Unraveling MDM4 Haploinsufficiency: A Novel TP53-Dependent Mechanism Driving Bone Marrow Failure Syndromes

By MedXY 07/17/2026

MDM4 haploinsufficiency activates p53, causing diverse bone marrow failure phenotypes and hypocellular MDS, highlighting the pivotal MDM4-p53 axis in hematopoietic regulation and potential targets for intervention.

news OB/GYN & Women’s Health Oncology

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

By MedXY 06/26/2026

This international study reveals that many patients with platinum-sensitive recurrent ovarian cancer achieve durable, progression-free survival exceeding 5 years on PARP inhibitors, even after treatment discontinuation, with a low risk of secondary hematologic malignancies.

Hematology-Oncology news Rheumatology

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

By MedXY 10/14/2025

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use and need for prospective trials.

Clinical Updates Hematology-Oncology news Specialties

Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS

By MedXY 09/21/2025

A phase 2 trial demonstrates that oral hypomethylating agent ASTX727, with optional donor lymphocyte infusion, shows encouraging disease-free survival and manageable safety after stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome.

Clinical Updates Hematology-Oncology news

Oral Decitabine and Cedazuridine as Maintenance Therapy Post-HSCT in Very High-Risk AML and MDS: Insights from the GFM-DACORAL-DLI Phase 2 Trial

By MedXY 09/21/2025

A phase 2 trial demonstrates that oral decitabine and cedazuridine maintenance following hematopoietic stem-cell transplantation may improve disease-free survival in very high-risk AML and MDS patients with manageable safety.

$Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results$

Clinical Updates Hematology-Oncology news Specialties

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results

By MedXY 08/02/2025

The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.